Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations

References

• LönnrothKRoglicGHarriesADImproving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practiceLancet Diabetes Endocrinol20142973073925194886
   PubMed Web of Science ®Google Scholar
• OlmosPDonosoJRojasNTuberculosis and diabetes mellitus: a longitudinal-retrospective study in a teaching hospitalRev Med Chil19891179979983 Spanish2519480
   PubMed Web of Science ®Google Scholar
• SwaiABMcLartyDGMugusiFTuberculosis in diabetic patients in TanzaniaTrop Doct19902041471502284664
   PubMed Web of Science ®Google Scholar
• RizaALPearsonFUgarte-GilCClinical management of concurrent diabetes and tuberculosis and the implications for patient servicesLancet Diabetes Endocrinol20142974075325194887
   PubMed Web of Science ®Google Scholar
• SalindriADKipianiMKempkerRRDiabetes reduces the rate of sputum culture conversion in patients with newly diagnosed multidrug-resistant tuberculosisOpen Forum Infect Dis201633ofw12627419188
   PubMed Web of Science ®Google Scholar
• HsuAHLeeJJChiangCYLiYHChenLKLinCBDiabetes is associated with drug-resistant tuberculosis in Eastern TaiwanInt J Tuberc Lung Dis201317335435623228433
   PubMed Web of Science ®Google Scholar
• DuangrithiDThanachartwetVDesakornVImpact of diabetes mellitus on clinical parameters and treatment outcomes of newly diagnosed pulmonary tuberculosis patients in ThailandInt J Clin Pract201367111199120923750554
   PubMed Web of Science ®Google Scholar
• KangYAKimSYJoKWImpact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosisRespiration201386647247823689646
   PubMed Web of Science ®Google Scholar
• Sirturo® (delamanid) tablets [prescribing information]BeerseJanssen-Cilag Int. N.V.2012
   Google Scholar
• Deltyba® (delamanid) film-coated tablets [prescribing information]MunchenOtsuka Novel Products GmbH2014
   Google Scholar
• Centers for Disease Control and PreventionProvisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosisMMWR Recomm Rep201362RR–09112
   Google Scholar
• WHOThe use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance2014 Available from: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdfAccessed August 16, 2016
   Google Scholar
• WHOThe use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance2012 Available from: http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdfAccessed August 16, 2016
   Google Scholar
• van CrevelRDockrellHMTANDEM ConsortiumUnderstanding diabetes and tuberculosisLancet Diabetes Endocrinol20142427027224703039
   PubMed Web of Science ®Google Scholar
• DostalekMAkhlaghiFPuzanovovaMEffect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugsClin Pharmacokinet201251848149922668340
   PubMed Web of Science ®Google Scholar
• NijlandHMRuslamiRStalenhoefJEExposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetesClin Infect Dis200643784885416941365
   PubMed Web of Science ®Google Scholar
• KumarHKannanTChandrasekaranVPharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in IndiaInt J Tuberc Lung Dis20162091236124127510252
   PubMed Web of Science ®Google Scholar
• KarbownikASzałekESobańskaKGrabowskiTWolcAGrześkowiakEThe alteration of pharmacokinetics of erlotinib and OSI420 in type 1 diabetic rabbitsPharmacol Rep201668596496827372922
   PubMed Web of Science ®Google Scholar
• McLeaySCVisPvan HeeswijkRPGreenBPopulation pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drugAntimicrob Agents Chemother20145895315532424957842
   PubMed Web of Science ®Google Scholar
• RouanMCLounisNGeversTPharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosisAntimicrob Agents Chemother20125631444145122155815
   PubMed Web of Science ®Google Scholar
• GlerMTSkripconokaVSanchez-GaravitoEDelamanid for multidrug-resistant pulmonary tuberculosisN Engl J Med2012366232151216022670901
   PubMed Web of Science ®Google Scholar
• LewisJMSloanDJThe role of delamanid in the treatment of drug-resistant tuberculosisTher Clin Risk Manag20151177979125999726
   PubMed Web of Science ®Google Scholar
• SasabeHShimokawaYShibataMAntitubercular agent delamanid and metabolites as substrates and inhibitors of ABC and solute carrier transportersAntimicrob Agents Chemother20166063497350827021329
   PubMed Web of Science ®Google Scholar
• FieldSKSafety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB)Clin Med Insights Ther201355137149
   Google Scholar
• ShimadaTYamazakiHMimuraMInuiYGuengerichFPInterindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 CaucasiansJ Pharmacol Exp Ther199427014144238035341
   PubMed Web of Science ®Google Scholar
• RentonKWCytochrome P450 regulation and drug biotransformation during inflammation and infectionCurr Drug Metab20045323524315180493
   PubMed Web of Science ®Google Scholar
• AitkenAERichardsonTAMorganETRegulation of drug-metabolizing enzymes and transporters in inflammationAnnu Rev Pharmacol Toxicol20064612314916402901
   PubMed Web of Science ®Google Scholar
• XuDXWangJPSunMFChenYHWeiWLipopolysaccharide downregulates the expressions of intestinal pregnane X receptor and cytochrome p450 3a11Eur J Pharmacol20065361–216217016556443
   PubMed Web of Science ®Google Scholar
• Sirturo® (bedaquiline) tablets [briefing package]Silver Spring, MDFDA2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329258.pdfAccessed August 27, 2016
   Google Scholar
• KlattSFrommMKönigJTransporter-mediated drug–drug interactions with oral antidiabetic drugsPharmaceutics20113468070524309303
   PubMedGoogle Scholar
• Cycloset® (bromocriptine) tablets [prescribing information]LavalValeant Pharmaceuticals International Inc1978
   Google Scholar
• KimKAParkJYInhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomesDrug Metab Dispos20033191090109212920163
   PubMed Web of Science ®Google Scholar
• Drugbank.ca [homepage on the Internet]Drugbank: gliquidone Available from: http://www.drugbank.ca/drugs/DB01251Accessed August 26, 2016
   Google Scholar
• Cholestagel® (colesevelam) film-coated tablets [prescribing information]NaardenGenzyme Europe B.V.2004
   Google Scholar
• HolsteinABeilWOral antidiabetic drug metabolism: pharmacogenomics and drug interactionsExpert Opin Drug Metab Toxicol20095322524119331589
   PubMed Web of Science ®Google Scholar
• SchronerZJavorskyMKozarovaMTkacIPharmacogenetics of oral antidiabetic treatmentBratisl Lek Listy2011112844144621863614
   PubMed Web of Science ®Google Scholar
• RuzilawatiABGanSHCYP3A4 genetic polymorphism influences repaglinide’s pharmacokineticsPharmacology201085635736420523106
   PubMed Web of Science ®Google Scholar
• ChoiYHLeeULeeBKLeeMGPharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2Br J Pharmacol2010161481582920860661
   PubMed Web of Science ®Google Scholar
• LeeJHKangHELeeMGPharmacokinetic interaction between telithromycin and metformin in diabetes mellitus ratsXenobiotica201040321722420039777
   PubMed Web of Science ®Google Scholar
• WooSLXuHLiHMetformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesityPLoS One201493e9111124638078
   PubMed Web of Science ®Google Scholar
• PatelKForetzMMarionAThe LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liverNat Commun20145453525088745
   PubMed Web of Science ®Google Scholar
• CameronARMorrisonVLLevinDAnti-inflammatory effects of metformin irrespective of diabetes statusCirc Res2016119565266527418629
   PubMed Web of Science ®Google Scholar
• RodbardHWJelleingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar
• StentzFBUmpierrezGECuervoRKitabchiAEProinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crisesDiabetes20045382079208615277389
   PubMed Web of Science ®Google Scholar
• NiaziAKKalraSDiabetes and tuberculosis: a review of the role of optimal glycemic controlJ Diabetes Metab Disord20121112823497638
   PubMedGoogle Scholar
• DuckworthWCKitabchiAEInsulin metabolism and degradationEndocr Rev1981222102337028472
   PubMed Web of Science ®Google Scholar
• FerranniniEWahrenJFaberOKFeligPBinderCDeFronzoRASplanchnic and renal metabolism of insulin in human subjects: a dose-response studyAm J Physiol19832446E517E5276344651
   PubMed Web of Science ®Google Scholar
• RabkinRRyanMPDuckworthWCThe renal metabolism of insulinDiabetologia19842733513576389240
   PubMed Web of Science ®Google Scholar
• RabkinRSimonNMSteinerSColwellJAEffect of renal disease on renal uptake and excretion of insulin in manN Engl J Med197028241821875409813
   PubMed Web of Science ®Google Scholar
• Humalog® (insulin lispro) injection [prescribing information]Indianapolis, INEli Lilly and Company2011
   Google Scholar
• NovoLog® (insulin aspart) injection [prescribing information]Princeton, NJNovo Nordisk Inc2011
   Google Scholar
• Apidra® (insulin glulisine) injection [prescribing information]Bridgewater, NJSanofi-Aventis2009
   Google Scholar
• HelmsKLKelleyKWInsulin glulisine: an evaluation of its pharmacodynamic properties and clinical applicationAnn Pharmacother200943465866819336657
   PubMed Web of Science ®Google Scholar
• Lantus® (insulin glargine) injection [prescribing information]Bridgewater, NJSanofi-Aventis2007
   Google Scholar
• Levemir® (insulin detemir) injection [prescribing information]BagsvaerdNovo Nordisk Inc2015
   Google Scholar
• Tresiba® (insulin degludec) injection [prescribing information]BagsvaerdNovo Nordisk Inc2013
   Google Scholar
• HavelundSPlumARibelUThe mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulinPharm Res20042181498150415359587
   PubMed Web of Science ®Google Scholar
• ArcherMSteinvoortCOderdaGGlucagon-like peptide-1 (GLP-1) receptor agonists. Drug class review2013 Available from: http://www.health.utah.gov/pharmacy/ptcommittee/files/Criteria%20Review%20Documents/05.13/05.13%20GLP1%20Receptor%20Agonist%20Drug%20Class%20Review.pdfAccessed August 18, 2016
   Google Scholar
• Saxenda® (liraglutide) injection [prescribing information]BagsvaerdNovo Nordisk Inc2015
   Google Scholar
• SymlinPen® (pramlintide acetate) injection [prescribing information]LondonAstraZeneca2015
   Google Scholar
• FoxGJMenziesDA review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosisInfect Dis Ther20132212314425134476
   PubMedGoogle Scholar
• GrahamDJStaffaJAShatinDIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugsJAMA2004292212585209015572716
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS InvestigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• SkottheimIBGedde-DahlAHejazifarSHoelKAsbergAStatin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitroEur J Pharm Sci2008334–531732518294823
   PubMed Web of Science ®Google Scholar
• MarquesMPCoelhoEBDos SantosNAGeleileteTJLanchoteVLDynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitusEur J Clin Pharmacol200258960761412483453
   PubMed Web of Science ®Google Scholar
• DiaconAHPymAGrobuschMThe diarylquinoline TMC207 for multidrug-resistant tuberculosisN Engl J Med2009360232397240519494215
   PubMed Web of Science ®Google Scholar
• DiaconAHDonaldPRPymARandomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistanceAntimicrob Agents Chemother20125663271327622391540
   PubMed Web of Science ®Google Scholar
• HellerSDarpöBMitchellMIConsiderations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: a report from the Cardiac Safety Research ConsortiumAm Heart J20151701233526093861
   PubMed Web of Science ®Google Scholar
• SegalaESougakoffWNevejans-ChauffourAJarlierVPetrellaSNew mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structureAntimicrob Agents Chemother20125652326233422354303
   PubMed Web of Science ®Google Scholar
• HartkoornRCUplekarSColeSTCross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosisAntimicrob Agents Chemother20145852979298124590481
   PubMed Web of Science ®Google Scholar
• PymASDiaconAHTangSJTMC207-C209 Study GroupBedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosisEur Respir J201647256457426647431
   PubMed Web of Science ®Google Scholar
• AndriesKVillellasCCoeckNAcquired resistance of Mycobacterium tuberculosis to bedaquilinePLoS One201497e10213525010492
   PubMed Web of Science ®Google Scholar
• BloembergGVKellerPMStuckiDAcquired resistance to bedaquiline and delamanid in therapy for tuberculosisN Engl J Med2015373201986198826559594
   PubMed Web of Science ®Google Scholar
• AlmeidaDIoergerTTyagiSMutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosisAntimicrob Agents Chemother20166084590459927185800
   PubMed Web of Science ®Google Scholar
• DiaconAHPymAGrobuschMPTMC207-C208 Study GroupMultidrug-resistant tuberculosis and culture conversion with bedaquilineN Engl J Med2014371872373225140958
   PubMed Web of Science ®Google Scholar
• BenderADThe effect of increasing age on the distribution of peripheral blood flow in manJ Am Geriatr Soc196513319219814270624
   PubMed Web of Science ®Google Scholar
• WarrenPMPeppermanMAMontgomeryRDAge changes in small-intestinal mucosaLancet197828094849850
   PubMed Web of Science ®Google Scholar
• CorazzaGRFrazzoniMGattoMRGasbarriniGAgeing and small-bowel mucosa: a morphometric studyGerontology19863216065
   PubMed Web of Science ®Google Scholar
• FülöpTJrWórumICsongorJFórisGLeöveyABody composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjectsGerontology19853116143972257
   PubMed Web of Science ®Google Scholar
• ChahineEBKaraouiLRMansourHBedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosisAnn Pharmacother201448110711524259600
   PubMed Web of Science ®Google Scholar
• TolmanKGFonsecaVDalpiazATanMHSpectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver diseaseDiabetes Care200730373474317327353
   PubMed Web of Science ®Google Scholar
• MerrellMDCherringtonNJDrug metabolism alterations in nonalcoholic fatty liver diseaseDrug Metab Rev201143331733421612324
   PubMed Web of Science ®Google Scholar
• RodighieroVEffects of liver disease on pharmacokinetics. An updateClin Pharmacokinet199937539943110589374
   PubMed Web of Science ®Google Scholar
• MinakerKLRoweJWPotassium homeostasis during hyperinsulinemia: effect of insulin level, beta-blockade, and ageAm J Physiol19822426E373E3776124125
   PubMedGoogle Scholar
• ChopraSKewalADoes hypoglycemia cause cardiovascular events?Indian J Endocrinol Metab201216110210422276259
   PubMedGoogle Scholar
• PintavornPCookWJProgressive renal insufficiency associated with amiodarone-induced phospholipidosisKidney Int200874101354135718528322
   PubMed Web of Science ®Google Scholar
• LeitingerNThe role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humansSubcell Biochem20084932535018751917
   PubMedGoogle Scholar
• JohnsonJNAckermanMJQTc: how long is too long?Br J Sports Med200943965766219734499
   PubMed Web of Science ®Google Scholar
• IanniniPBCardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc intervalExpert Opin Drug Saf20021212112812904146
   PubMedGoogle Scholar
• DumaineRRoyMLBrownAMBlockade of HERG and Kv1.5 by ketoconazoleJ Pharmacol Exp Ther199828627277359694927
   PubMed Web of Science ®Google Scholar
• StumpeKOKollochRHiguchiMKrückFVetterHHyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine controlLancet19772803121121469827
   PubMed Web of Science ®Google Scholar
• SowersJRDopaminergic control of circadian norepinephrine levels in patients with essential hypertensionJ Clin Endocrinol Metab1981536113311377298797
   PubMed Web of Science ®Google Scholar
• TolmanKGChandramouliJHepatotoxicity of the thiazolidinedionesClin Liver Dis20037236937912879989
   PubMedGoogle Scholar
• HsiaoSHLiaoLHChengPNWuTJHepatotoxicity associated with acarbose therapyAnn Pharmacother200640115115416317107
   PubMed Web of Science ®Google Scholar
• SlimRBen SalemCZamyMBiourMPioglitazone-induced acute rhabdomyolysisDiabetes Care2009327e8419564463
   PubMedGoogle Scholar
• Actos® (pioglitazone) tablets [prescribing information]TaastrupTakeda2007
   Google Scholar
• AndriesKVerhasseltPGuillemontJA diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosisScience2005307570722322715591164
   PubMed Web of Science ®Google Scholar
• AlsultanAPeloquinCATherapeutic drug monitoring in the treatment of tuberculosis: an updateDrugs201474883985424846578
   PubMed Web of Science ®Google Scholar
• PeloquinCATherapeutic drug monitoring in the treatment of tuberculosisDrugs200262152169218312381217
   PubMed Web of Science ®Google Scholar
• HeysellSKMooreJLKellerSJHouptERTherapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USAEmerg Infect Dis201016101546155320875279
   PubMed Web of Science ®Google Scholar
• GualanoGCaponeSMatteelliAPalmieriFNew antituberculosis drugs: from clinical trial to programmatic useInfect Dis Rep201682656927403268
   PubMedGoogle Scholar